The power of this strategy became first evident by studies of the Baltimore laboratory that modelled the effect of the chronic myeloid leukaemia (CML)-associated BCR-ABL fusion gene [111]. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.